



Grant Application Guidance

Broader and deeper protein content for optimized discovery potential – capable of 11,000 protein measurements



Introduction

Typically, research is funded through grants or budgets. This financial support plays a crucial role in advancing research. Consequently, projects often require clear explanations and justification. This resource aims to provide guidance for those seeking funding for projects that utilize the SomaScan Assay®, either from SomaLogic's CLIA-certified, CAP-accredited laboratory or any of our Authorized Sites around the world.

Platform Overview

The SomaScan Assay is a proteomic platform based on modified aptamers. Aptamers are short, synthetic sequences of DNA that exhibit a natural affinity to proteins. These aptamers are modified to provide exquisite specificity to specific protein targets. Known as "Slow Off-rate Modified Aptamers" or SOMAmer® Reagents, they offer 11,000 total protein measurements of circulating proteins from a single sample.

SOMAmer Reagents are selected via the SELEX process based on their strong binding affinity to a protein target. The reproducibility and stability of the SomaScan Assay are regularly tested to maintain consistency over time and from assay to assay. Specificity testing includes:

- In silico selection, procurement (when available), and direct SOMAmer Reagent binding experiments in buffer with "relevant relative" proteins.

- "Pulldown" assays followed by mass spectrometry-based and SDS gel-based analysis of the protein(s) bound by the SOMAmer Reagent from biological matrices (5% of the menu).
- Binding affinity testing against closely related proteins to determine the level of cross-reactivity for over 1/3 of the menu. Any binding to another protein is reported in the annotated menu.
- Cis-pQTL analysis to confirm specificity, with over 2,000 protein targets confirmed.
- Correlation with antibody-based detection methods such as ELISA to confirm specificity.
- Individual SOMAmer Reagents are available for further investigation.


With the ability to analyze half the genetically encoded human proteome, this pioneering platform surpasses all other technologies. This unparalleled coverage unlocks a new depth of molecular insights, empowering researchers to make informed decisions, drive better outcomes, and ultimately revolutionize healthcare.

Want to learn more about how the assay works? Download the [SomaScan Assay V5.0 Technical Note](#)

Want to view the SomaScan Menu? Visit <https://menu.somalogic.com/>

Workflow

The SomaScan Assay enables you to process and analyze data following the workflow outlined below.



*Provided as an estimate. ADAT file-generation lead-time estimates are subject to fluctuate depending on demand.

Funding Agencies

Selecting the most suitable Funding Agency is paramount to securing your funds and can be more challenging than it seems. Grant applications may face rejection if the incorrect research funding body is targeted. Therefore, it is essential to meticulously evaluate options and research which agency aligns best with your project. Explore the following Funding Agency resources to assist you in making an informed choice.

How to Apply for NIH Grants:

[How to Apply - Application Guide | grants.nih.gov](#)

How to get funding for lab research & links:

[How to Get Funding for Lab Research in 2022 | Excedr](#)

Supporting Data

Publications serve as invaluable resources when seeking grant funding. With over 800 peer-reviewed publications available, you can enhance your grant application with evidence of market validation. These publications underscore that SomaLogic is a proven platform leveraging proteins to unveil biological and disease information across numerous specialties, including Cardiovascular, Kidney, Aging, Respiratory, Neurobiology, and more. Since 2010, nearly half a million samples have been analyzed. Explore how the world's leading life science and pharmaceutical research organizations are revolutionizing their discovery and validation pipelines with our groundbreaking proteomic technologies by visiting the following link:

[SomaLogic Publications](#)



SL00000778 Rev2: 2024-01

Grant Application Guidance – End User

SomaLogic®, SomaScan®, SOMAmer®, SomaSignal® and associated logos are trademarks of SomaLogic Operating Co., Inc. and any third-party trademarks used herein are the property of their respective owners. For Research Use Only (RUO). Not intended for diagnostic or patient management purposes. SomaLogic Operating Co., Inc. is accredited to ISO 15189:2012, ISO 27001, ISO 9001, and is a CLIA-certified, CAP-accredited laboratory.

© 2024 SomaLogic Operating Co., Inc. | 2945 Wilderness Pl, Boulder, CO 80301 | Ph 303 625 9000 | www.somallogic.com